Novartis' targeted leukemia drug, Scemblix, could set a new standard in front-line treatment for chronic myeloid leukemia (CML) after outperforming traditional TKI drugs in the ASC4FIRST study presented at the ASCO 2024 conference. The study highlights Scemblix's potential to play a larger role in Novartis' growth strategy, as discussed by CEO Vas Narasimhan in an interview with BioCentury Editor in Chief Simone Fishburn. Major data readouts for Scemblix and another drug, remibrutinib, were also part of Novartis' presentations at ASCO 2024 and the EAACI Congress. Novartis' stock symbol is $NVS.
. @Novartis’ Scemblix could be headed for first-line use in chronic myeloid #leukaemia after outperforming TKI drugs in the ASC4FIRST study presented at #ASCO24. #oncology https://t.co/Y4uvIdJT08
Novartis study points to larger role for targeted leukemia drug https://t.co/x0sBn2r2zC $NVS by @NedPagliarulo
How Vas Narasimhan views a pair of readouts in @Novartis’ growth strategy. $NVS CEO speaks with BioCentury Editor in Chief @FishburnSimone on major data readouts for Scemblix and remibrutinib at #ASCO24 & #EAACI Congress. @EAACI_HQ @ASCO #CML https://t.co/rtd9qT24B1
Novartis study points to larger role for targeted leukemia drug https://t.co/QLhmPc9Cbb by @NedPagliarulo $NVS #ASCO2024
First #ASCO24 story: Scemblix could set new standard in front-line leukaemia $NVS via @ApexOnco https://t.co/MsRVXyeL6J